Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
To evaluate the objective response rate (ORR; confirmed complete response(CR) or partial response (PR)) of gefitinib using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in Caucasi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Double-blind, Multi-centre, Active-Controlled (15, 30, and 45mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar (0.5 and 1 mg) in Patients with Type 2 Diabetes Mellitus
The primary objective is to monitor the long-term safety and tolerability of tesaglitazar (0.5 and 1 mg) versus pioglitazone (15, 30 and 45 mg), with or without other oral anti-diabetic drugs, when ad...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Phase II Open-Label, Randomised, Comparative, International Multicentre Study to Compare the Safety and Efficacy of Two Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer Who Have Failed Previous Platinum Based Chemotherapy
To compare the efficacy of 2 different dose levels of AZD2281 versus liposomal doxorubicin in patients with advanced BRCA1 or BRCA2 associated ovarian cancer. This will be assessed by the following:...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 µg/inhalation, two inhalations twice daily plus as-needed compared with Seretide™ Diskus™ 50/500 µg/inhalation, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed - a 6-month randomised, double-blind, parallel-group, active controlled, multinational phase IIIB study in adult and adolescent patients with persistent asthma
The primary objective of this study is to compare the efficacy of two inhalations of Symbicort Turbuhaler 160/4.5 µg/inhalation twice daily plus Symbicort Turbuhaler 160/4.5 µg/inhalation as-needed, ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD
The primary objective of the study is to determine the efficacy of AZD9056 (single oral 400 mg dose) in moderate to severe COPD patients during a 4-week treatment period.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Multi-centre, Double-blind, Randomised, Placebo-controlled, Single-dose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of AZD1305 in Patients Undergoing an Invasive Electrophysiological Procedure
Evaluate the effects of AZD1305, compared to placebo, on the left atrial effective refractory period (LAERP), in patients undergoing an invasive electrophysiological procedure (EP).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Esomeprazole Magnesium 20 mg and 40 mg in a Pediatric Population of 12 to 17 Year-Olds with Gastroesophageal Reflux Disease (GERD) or Symptoms of GERD
Primary Objective: To determine AUC after single and repeated (multiple) oral doses of 20 mg and 40 mg esomeprazole magnesium in 12- to 17-year-olds inclusive with GERD or symptoms of GERD.
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A study to evluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia
To assess the long-term safety and tolerability of rosuvastatin 20 mg in pediatric patients with Homozygous Familial Hypercholesterolemia (HoFH).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Single-Blind, Randomised, Parallel-Group, Single-Centre Pharmacokinetic and pH-Monitoring Study of Esomeprazole in Infants up to 24 Months of Age
Primary objectives To assess the pharmacokinetics of esomeprazole and its efficacy in controlling intragastric pH in infants.
Country
None
organs
None
Specialty
None
More information
Woman and Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 5 ans
Étude D419BC00001 : étude de phase 3 randomisée évaluant l’efficacité du durvalumab en monothérapie associé à du trémélimumab par rapport à une chimiothérapie standard chez des patients ayant un cancer urothélial de stade 4 non résécable.
Le carcinome urothélial est le type le plus fréquent de cancer de la vessie, il représente plus de 90 % de tous les cancers de la vessie. Il peut subvenir dans n’importe quelle partie de l’appareil ur...
Country
France
organs
Rein
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next